Bispecific T-cell engaging antibodies (BiTES), comprising dual anti-CD3 and anti-tumor antigen scFv fragments, are important therapeutic agents for the treatment of cancer. The dual scFv construct for BiTES requires proper protein folding while their small molecular size leads to rapid kidney clearance. Here we show that an intact (150 kDa) anti-tumor antigen antibody to CEA was joined in high yield (ca. 30%) to intact (150 kDa) anti-murine and anti-human CD3 antibodies using hinge region specific Click chemistry to form dual-specific, bivalent BiTES (db 3
Introduction
The concept of directing T-cells to tumors with bispecific antibodies that incorporate an anti-CD3 antibody and an anti-tumor antigen antibody into a single molecule was first explored 25 years ago when recombinant DNA technologies made the genetic engineering of bispecific antibodies possible [1] . Today the most widely used BiTE (Bispecific T-cell Engaging antibodies) constructs join two single chain Fv fragments together with a linker to form a 50kda protein. Examples of tumor target antigens include CD19, EpCAM, Her2/neu, EGFR, CEA, and more [1] . The BiTE anti-CD19/anti-CD3 (Blinatumomab) has had remarkable success in the treatment of several B-cell malignancies, suggesting that directing T-cell (and other effector cells) to tumors by a bispecific antibody approach can be effective even against solid tumors [2] .
Possible limitations of the therapy include the small molecular size that requires constant infusion of rather large amounts of BiTEs, the poly-activation of endogenous TCRs may lead to off target toxicity, and the lack of an engagement of a co-stimulus such as CD28 on the T-cell may limit effective tumor killing. An alternate approach pioneered by Lum and associates [3] utilized chemical conjugation with protein surface cross-linking agents on intact antibodies (eg., anti-CD3 and anti-CA125) that were coated onto IL-2 activated autologous T-cells. In spite of the high heterogeneity of the resulting bispecific antibodies, advantages of the approach were that only microgram amounts of antibody were required for coating the T-cells and the therapy was considered a cell-based therapy by the FDA since it involved infusion of T-cells and not antibody infusion. Thus, this approach used clinically tested humanized antibodies as a starting point, avoiding the need to engineer dual scFVs that may be difficult to express in the amounts needed for therapy. Furthermore, the infusion of bispecific antibody coated T-cells is a cellbased therapy similar, and perhaps complimentary, to infusion of CAR T cells. However, to bring the approach into widespread use, it is important to develop a high yield conjugation method that does not lead to a complex mixture of bispecific antibodies.
To overcome this challenge, we show here an efficient approach to conjugate two antibodies alkylated at their sulfhydryl reduced hinge regions with two complimentary Click reagents, bromoacetamido-dibenzocyclooctyne (DBCO) and bromoacetamido-PEG 5 -azide. To demonstrate feasibility, we selected the humanized anti-CEA antibody T84.66-M5A (M5A) and anti-CD3 antibody OKT3, both extensively used in the clinic [4, 5] . Given their dual specifities and retention of bivalent binding, we propose to call them dbBiTEs. The 300 kDa product when purified away from contaminating 150 kDa species, shows distinctive six-lobed antibody particles on electron microscopy that fit atomic scale models, labels both CEA and CD3 positive cells, and when coated on activated T-cells, kills CEA positive cells in cytotoxicity assays. In vivo PET imaging shows excellent targeting to tumor targets, and in the preliminary therapy studies, killing of CEA positive tumors.
Results

Generation of dbBiTES.
Building on the approach developed by Lum et al. [3] who randomly cross-linked two intact antibodies (anti-CD3 and anti-CA125) using Traut's reagent and sulfosuccinimidyl 4-(Nmaleimidomethyl) cyclohexane-1-carboxylate to redirect T-cell therapy to tumor targets, we first generated bispecific antibodies by cross-linking two intact antibodies at their hinge regions using Click chemistry (Scheme 1). The use of Click chemistry allows the generation of a bispecific antibody product with improved yields and molecular characteristics, a much-desired feature in bringing new products to the clinic. To distinguish the product from conventional BiTEs built from monovalent single chain Fv (scFv) fragments, we suggest the name dbBiTE, for dual specific bivalent BiTE. Briefly, OKT3, a murine anti-human CD3 antibody widely used in the clinic [4] was reduced at its hinge region cysteines under non-denaturing conditions, alkylated at its reduced hinge region cysteines with a bromoacetamido-PEG 5 -azido derivative and conjugated to our humanized anti-CEA M5A antibody [5] that was similarly reduced and alkylated with a bromoacetamido-DIBO derivative. Each of the derivatized IgGs were analyzed by electrospray ionization mass spectrometry to confirm their degree of derivatization (Supplementary Fig S1) .
In both cases the heavy chains contained at least 2 Click derivatives. The Clicked dbBiTE was isolated in a yield of 30% by size exclusion chromatography (SEC, peak 1, 300 kDa, Fig 1A) . A second peak of MW 150 kDa was obtained in a yield of 60%. The peaks were analyzed by nondenaturing SDS gel electrophoresis to further verify their molecular sizes compared to the two intact antibodies (Fig 1B and C) . The 150 kDa peak was shown to be mainly a monovalent bispecific antibody that was poorly active in functional studies (redirected T-cell cytotoxicity) and was broken down into lower molecular weight fragments by SDS gel electrophoresis (data not shown). Therefore, we focused on the novel dbBiTE (300 kDa) since it retains the inherent avidity (bivalent binding) of both parent antibodies. Peak 1 was re-purified by SEC to remove contaminating peak 1. Rechromatography of peak 1 over the course of several weeks showed no evidence of instability consistent with their covalent linkages (data not shown).
Particle size by electron microscopy.
Purified peak 1 was analyzed by transmission electron microscopy (TEM) to determine the particle size and morphology (Fig 2A) . Most particles exhibited a 5-lobed morphology suggesting that the predicted sixth lobe (based on 3 lobes per Ab times 2) was hidden under or above the plane of the 2D image. This morphology is more clearly visualized on the 2D averaged analysis (Fig 2B) . Using tilt axis imaging, it was possible to show a representative 3D image (Fig 2C) . A closer examination of the particles shown in Fig 2A reveals multiple orientations of 6-lobed particles (further data available upon request), always with the sixth lobe appearing as additional density in the center of the particle. These images are compatible with the random landing of 6-lobed 3D particles on a 2D grid in which one lobe is lying above or below the main body of the particle. In addition to the majority of 6-lobed particles found, a small percentage (<10%) of particles with a side-to side orientation were observed. We speculate that these are due to Click chemistry occurring between adjacent light chains (1 cysteine per light chain) at their hinge regions, rather than the more frequent heavy chain hinge regions (3 cysteines per heavy chain in human IgG1).
Molecular simulations of dbBiTE structure.
We performed multi-scale molecular dynamics simulations to generate an atomic level structural model examining how the two IgGs fit into a dbBiTE joined by Click chemistry at their hinge region cysteines. We generated a coarse grain homology model of the two IgGs (Supplemental Fig S2) that used the coarse grain simulation method Martini to optimize the packing of these two moieties. The dynamics of the two IgGs approaching each other and docking at their hinge regions is shown in Supplemental movie SM1. The optimized structural model shows the two IgGs joined by at least two pairs of Clicked hinge region cysteines (Fig 3   and supplemental movies SM2 and 3) . The final docked dbBiTES were then oriented to fit within the observed 6-lobed particles found on EM (Supplemental Fig S3) . The superposition of the dbBiTE structural model thus generated, onto the particles imaged by EM strongly supports the idea that two IgGs can indeed be joined together at their hinge regions in spite of the size of their 3 globular domains.
In vitro binding and cytotoxicity of dbBiTEs to CEA positive targets.
Since it was important to demonstrate that both antibody specificities were retained in the dbBiTE, in vitro binding studies were performed comparing the starting antibodies to the dbBiTE on CEA and CD3 positive targets (Fig 4A-B) . The results demonstrate that dbBiTES are able to bind both CEA and CD3 positive target cells. In vitro cytotoxicity was demonstrated by coating activated human T-cells with dbBiTES (1 µg per 10M cells per mL) and incubation with CEA positive targets at the indicated E:T ratios (Fig 4C) . Effective killing was observed as low as an E:T of 1.25:1 with maximal killing at an E:T of 10:1. Analysis of the supernatants revealed a significant release of IFNγ compared to controls (Fig 4D) demonstrating that the dbBiTE coated activated T-cells were able to produce a functional cytokine in response to target engagement. When the coating capacity of activated T-cells with dbBiTEs was tested by flow analysis, it was found that as little as 1 ng/mL of dbBiTE incubated with 10M T-cells per mL was detectable (Fig 4E) . Although the cytotoxicity of activated T-cells against CEA positive targets was detectable at this concentration, higher coating concentrations were more effective Fig S5) . The 150 kDa contaminant is likely a mixture of intact M5A and OKT3 or their Click conjugated half molecules. Since only the 300 kDa species shifted to a higher molecular complex on the addition of unlabeled CEA, we conclude that only the 300 kDa dbBiTE is immunoreactive.
When 64
Cu-DOTA labeled dbBiTE was injected into CEA positive tumor bearing mice, PET imaging revealed rapid uptake into both tumor and liver with evidence of blood pool in the heart at the earliest time point (Supplementary Fig S6) . At the terminal time of 44 hr, 15 %ID/g was found in tumor, 5 %ID/g in blood and 18 %ID/g in liver. Compared to our previously published PET images of 64 Cu-DOTA labeled M5A that showed about 45% ID/g in tumor, 10 %ID/ in blood and 12 %ID/g in liver at 44 hrs [6] , the faster clearance of dbBiTE from blood into liver may be due to liver recognition of the multiple Fc moieties on the dbBiTE.
Nonetheless, the PET imaging demonstrates excellent targeting of the dbBiTE to tumor, encouraging us to test the efficacy of the dbBiTE in vivo.
In vivo killing of CEA positive tumors.
A limited therapy study of dbBiTE coated T-cells was performed in CEA transgenic mice bearing the syngeneic colon cancer cell line MC38 transfected with CEA and luciferase. This model (minus the luciferase) has been previously described by us using the immunocytokine anti-CEA-IL-2 [7] . In order to test a biocompatible version of the dbBiTE in this model system, we generated a dbBiTE comprising rat anti-mouse CD3 and anti-CEA M5A (data not shown). 
Discussion
This study was initiated to extend the scope of BiTEs beyond the technology requiring genetically engineered dual scFvs, and beyond the approach of coating activated T-cells with a heterogenous mixture of bispecific antibodies. While genetically engineered BiTEs from dual scFv fragments to CD3 and either EpCAM or CD19 have shown significant anti-tumor activity in the clinic [8] [9] [10] , it is important to extend this approach to readily available intact tumor specific antibodies. In this regard, CEA is an excellent target for many solid tumors including colon, breast, pancreas, and medullary thyroid carcinoma [11] . Although several groups have generated anti-CD3/anti-CEA dual scFv BiTEs [12, 13] , their clinically utility is subject to several challenges common to all dual scFv BiTES. A major challenge is that the production of dual scFv BiTEs requires proper protein folding for subsequent large-scale production for clinical use. A second challenge is the need to continuously infuse these BiTEs for therapy due to their rapid blood clearance via the kidney. Since many humanized anti-tumor antibodies have become FDA approved therapeutics, it is highly desirable to generate bispecific antibodies directly from intact antibodies circumventing these two problems. First, there is no need to reengineer the bispecific BiTE, and if an intact anti-tumor IgG is FDA approved, one may obtain it from the pharmacy. Similarly, a murine anti-human CD3 antibody is commercially available and clinically tested [14] . Second, once combined into a bispecific format, their combined molecular weights (300 kda) would preclude blood clearance by the kidney. Although an attractive idea, many attempts to produce such antibodies retaining their dual specifities has been met with difficulty. Among the approaches, knobs-into-holes [15] , DuoBody [16] , and Cross- Traut's reagent, followed by the hetero-bispecific cross-linking agent sulfosuccinimidyl 4-(Nmaleimidomethyl) cyclohexane-1-carboxylate [3] . Although the cross-linked product had significant anti-tumor activity when coated on activated T-cells, the product itself was very heterogeneous. A better strategy at producing a more homogeneous cross-linked product was described by Patterson et al. for two IgGs [18] and their Fab fragments [18] . In this approach chemically reduced hinge region cysteines were derivatized with Click reagents that allowed a more specific crosslinking of two different IgGs together. In their study, two clinically available anti-tumor antibodies, anti-EGFR (Cetuximab) and anti-Her2 (Trastuzuab), that were conjugated by cysteine specific Click chemistry retained the specifities of both intact antibodies.
In our study, we demonstrate that cross-linking of murine anti-human OKT3, an IgG2a, to a humanized anti-CEA IgG1 resulted in a bispecific antibody that was isolated in high yield and retained high binding to cells expressing human CD3 or CEA. Importantly, since both antibodies retain both antigen combining arms, they retain the property of avidity, inherent to all intact antibodies, a feature that is lost with dual scFv BiTEs. To emphasize this feature, we have named them dbBiTES for their dual specific, bivalent properties. Since biological products are expected to meet high standards in terms of molecular characterization, it was important to analyze the physical characetictics of dbBiTEs. EM characterization of the resultant 300 kDa particles revealed a flexible six-lobed structure with considerable density at the hinge region, consistent with our expected model. Indeed, the structural model generated using molecular docking and dynamics of the two IgG antibodies was consistent with the EM analysis. and eluted at a flow rate of 0.5 mL/min in PBS. The two peaks (peak 1 and 2) were collected and further analyzed. Based on calibration with authentic standards, peak 1 has a molecular mass of 300 kDa and peak 2, 150 kDa. B. Peaks 1 and 2 from SE HPLC were run on nonreducing SDS gels to determine their molecular sizes compared to the standard IgG M5A. C.
The starting antibodies, anti-CEA M5A and anti-CD3 OKT3 were run as standards on SDS polyacrylamide gel electrophoresis alongside purified peak 1 dbBiTE.
Figure 2. Electron microscopy analysis of dbBiTES. A.
Representative EM of 300 kDa particles at 67,000 magnification. B. 2D average reconstruction of >100 6-lobed particles. IgG lobes arbitrarily labeled as 1-6, the 6 th lobe assumed out of the plane (z-axis) of the paper. C.
3D reconstruction of 6-lobed particles using tilt beam EM. Lobes labeled as above. 
Materials and methods
Materials.
Dibenzocyclooctyne-amine (BP-22066) and bromoacetamido-PEG 5 -azide (BP-21801)
were purchased from Broadpharm (San Diego, CA). Murine anti-human CD3 (OKT3;
InVivoMAb, BE0001-2) was from BioXCell (Lebanon, NH), and rat anti-murine CD3 (Cat no 100331, LEAF purified) from Biolegend (San Diego, CA).
Synthesis of bromoacetamido-DBCO.
To dibenzocyclooctyne-amine (DBCO-NH 2 ) (27.52mg, 0.1mmol) in 400µl dry DMF was added bromoacetic anhydride (41.0mg, 0.15mmol) and NaHCO 3 (25.2mg, 0.3mmol). After rotating at RT for 2h under Argon, the mixture was purified by a Gemini C18 column 
Alkylation of a reduced antibody with bromoacetamido-DBCO
The reduced OKT-3 was reacted with 20 fold molar excess bromoacetamido-DBCO at RT overnight under Argon. The excess bromoacetamido-DBCO was removed by dialyzing vs PBS (2L x5). The conjugation was confirmed by Agilent 6520 QTOF mass spectrometry. There was one DBCO per light chain and four DBCOs per heavy chain. Transmission electron microscopy and image analysis.
Alkylation of a reduced antibody with bromoacteamido-PEG 5 -azide
dbBiTEs were submitted for analysis to Nanoimaging Services, Inc. (San Diego, CA)
Samples were prepared on a thin layer of continuous carbon placed over a C-flat holey carbon grid (2.0/1.0; Protochips). A 3μl drop of purified protein (15 μg/ml in 50 mM Tris/150 mM NaCl, pH 7.5) was applied to a freshly plasma-cleaned grid for 20 seconds, blotted to a thin film using filter paper, and immediately stained with 2% (w/v) uranyl formate for 1 minute. The stain was then blotted away with filter paper and the grid subsequently air-dried. Transmission electron microscopy was performed using an FEI Tecnai T12 electron microscope operating at 120 kV equipped with an FEI Eagle 4k x 4k CCD camera. Images were collected at nominal magnifications of 110,000x (0.1 nm/pixel) and 67,000x (0.16 nm/pixel) using the automated image acquisition software package Leginon [19] . Images were acquired at a nominal underfocus of -1.6 μm to -0.9 μm or -1.4 µm to -0.6 µm and electron doses of approximately 25e-/Å 2 . An example of a typical field at a magnification of 67,000 is shown in Fig 2A. Image processing was performed using the Appion software package [20] . Contrast transfer functions (CTF) of the images were corrected using CTFFind4 [21] . Individual particles in the 67,000x images were selected using automated picking protocols, followed by several rounds of reference-free 2D alignment and classification based on the XMIPP [22] processing package to sort them into self-similar groups. An example of a 2D reconstructed image in shown in Fig 2B. A complete set is available upon request.
A random conical tilt 3D structure analysis was performed on 4000 average particles.
Over 50 different RCT reconstructions were computed in an attempt to resolve interpretable Individual particles were selected using automated picking protocols [20] on both the untilted and tilted images taken at 67,000x. Auto alignment was used to match particles across the tilted image pairs [23] . A reference-free alignment strategy based on the XMIPP processing package [22] was used to separate these particles into classes. RCT geometry [24] was used to reconstruct the 3-D structure of the particle pairs in exemplary class averages. The RCT maps presented in this report are based on 644-839 particles. The nominal resolution of both maps is on the order of ~45 Å according to the FSC0.5 resolution criterion. The Chimera visualization package [25] was used to produce the surface renderings of the maps.
Prediction of dbBiTE structure using multiscale simulations
In brief, the two antibody structures were separately modeled after the available crystal structure of mouse immunoglobulin. The docking between the two antibodies was accomplished using coarse-grain MD simulations, imposing attractive forces among the conjugating cysteine residues in the hinge regions of the two antibodies to facilitate binding. The resulting complex structure was then converted to atomistic resolution for comparison with the EM data.
The structures of the M5A and OKT3 antibodies ( Supplementary Fig S2A) were predicted using the crystal structure of mouse IgG2a as template (PDB ID: 1IGT) [26] , using the software MODELLER [27] . For docking, the two antibodies were initially separated by 100Å
and positioned with their hinge regions facing each other, as shown in Supplementary Fig S2A. The system was then converted to the Martini coarse-grained model [28] ( Supplementary Fig   S2B-C) using the CHARMM-GUI [29] . During the course of molecular dynamics, the internal structures of the Fc and Fab regions were preserved using an elastic network [30] , while the linker regions were made completely flexible. This allowed us to model the deformation of the hinge regions as the two antibodies approached each other to form the complex. To facilitate docking, we imposed distance restraints between the cysteine residues in the hinge regions of the two antibodies. Each M5A monomer has two cysteines in the lower hinge region connecting heavy chains, while OKT3 has three cysteines connecting heavy chains. We restrained the Cα carbons of the hinge region cysteines of the two antibodies using a flat-bottomed potential with an equilibrium distance of 15Å. Beyond 15Å, the restrained residues experienced an attractive elastic force with a force constant of 1000 KJ/mol, while no forces were experienced below 15Å.
The equilibrium distance for the restraint between the conjugated cysteines was determined from MD simulations of two cysteine residues connected by the click chemistry linker in aqueous solution. The equilibrium distance was chosen as the mean value in the distance distribution of the Cα carbons in this system (Supplementary Fig S2D) . We hypothesized that upon docking, at least one cysteine in the hinge region of one antibody will be conjugated to one cysteine of the other antibody via click chemistry. To recreate this condition, the system was simulated imposing the criterion that at least one of the distance restraints between the cysteine residues should be satisfied during dynamics.
The system was minimized for 6000 steps using steepest descent minimization, then heated up to 303K, followed by equilibration in the NPT ensemble for 10 ns (303K, 1 atm).
During equilibration, the protein atoms were restrained at their initial positions with a force constant of 4000 KJ/mol. The production MD was performed at 303K in the NPT ensemble for 500 ns using a time step of 20 ps, by imposing the distance restraints as described above. The MD simulations were performed using GROMACS 5.1 [31] . The final structure from the coarsegrained MD simulation (Supplementary Fig S2E) was converted to the all-atom structure using the scheme described in ref. [32] and visualized using PyMOL [33] .
Tumor cell lines culture and T cell activation
Human breast carcinoma MDA-MB-231 and murine breast carcinoma cell line E0771
and colon cancer cell line MC38 were stably transfected with a CEA expressing plasmid as described earlier [7] . All cell lines were maintained in DMEM supplemented with 10% fetal bovine serum and 100 U/ml penicillin/streptomycin. Unstained cells, or cells stained with secondary antibodies only served as negative controls.
OKT3 and rat anti mCD3 (BioLegend, CA) and M5A were used as positive controls followed by secondary antibodies staining performed as described above.
In vitro cytoxicity assay
Target cells were plated on 96-well plates at concentration 10x10^3 per well in 100uL of DMEM containing 10% FBS. After 3 or 18 hours, depending on cell line, 100uL of human activated and antibody coated PBMCs or mouse activated and antibody coated CD3 T cells were added to target cells in concentrations corresponding to final effector to target ratios 10:1, 5:1, 2.5:1 and 1.25:1. Controls with uncoated or anti-CD3 coated cells were used in the same ratios.
Cells were co-incubated for 18 hours at 37 o C followed by analysis of lactate dehydrogenase (LDH) release. The assay was performed following manufacturer's protocol (Takara, Japan) and relative cytotoxicity was calculated according to the same protocol.
In vivo tumor targeting with dbBiTE coated activated mouse T cells
These animal experiments were performed using CEA transgenic mice generated in
Beckman Research Institute at City of Hope National Medical Center as described before [7] .
Mouse care and experimental procedures were performed under pathogen-free conditions in PET imaging of a CEA positive tumor with 64 Cu radiolabed DOTA-dbBiTE dbBiTEs were conjugated with NHS-DOTA as previously described [6] .
Immunoreactivity to CEA was confirmed by addition of 64 Cu-DOTA-dbBiTE to CEA followed by SEC as shown in supplementary Fig S5C. Animal imaging studies were performed in NOD/SCID mice bearing s.c. LS-174T CEA positive tumors as previously described [6] . PET scans were acquired with an Inveon microPET/CT scanner (Siemens Medical Solutions). Mice were anesthetized with 2%-4% isoflurane in oxygen, placed on the PET scanner, and injected with a single intravenous dose of 100 µCi (10 µg) of 64 Cu-DOTA-dbBiTE in 1%
human serum albumin-buffered saline through a tail vein catheter. At the terminal time point, the mice were euthanized and biodistribution studies performed on the tissues indicated in supplementary Fig S6. 
